Company Description
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally.
The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis.
It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jun 18, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Kathy Lee-Sepsick |
Contact Details
Address: 3950 Johns Creek Court, Suite 100 Suwanee, Georgia 30024 United States | |
| Phone | 770 500 3910 |
| Website | femasys.com |
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001339005 |
| CUSIP Number | 31447E105 |
| ISIN Number | US31447E1055 |
| Employer ID | 11-3713499 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dov Elefant | Chief Financial Officer |
| John Canning | Chief Operating Officer |
| Mary An Merchant J.D., Ph.D. | Vice President of Counsel and Intellectual Property |
| Benjamin Dings | Vice President of Sales |
| Megan Eckerman | Senior Vice President of Global Marketing |
| Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor |
| Christine Thomas | Senior Vice President of Regulatory and Clinical Affairs |
| Dr. James H. Liu M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 6, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2026 | 8-K | Current Report |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 27, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 18, 2026 | SCHEDULE 13G | Filing |
| Jan 15, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 424B3 | Prospectus |